New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
08:31 EDTNVAXNovavax says BARDA continues contract for both seasonal, pandemic flu programs
Novavax announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority, or BARDA, has completed an In-Process Review of Novavax' contract covering the company's recombinant virus-like particle vaccine candidates for pandemic and seasonal influenza. The contractually-defined IPR was conducted by a team of U.S. Government experts, who provided input on Novavax' progress during the contract base period and plans for further development, including both near-term process development and manufacturing activities and longer-term clinical efforts. BARDA has notified the company that based on the results of the IPR, a milestone decision has been made to continue the contract for both the seasonal and pandemic influenza programs. In March 2011, Novavax was awarded a contract valued at up to $179M by BARDA for the advanced development of recombinant vaccines for the prevention of seasonal and pandemic influenza. In the midst of the contract's 3-year base period, valued at $97M, Novavax has been developing and testing its novel recombinant virus-like particle influenza vaccines to address BARDA's commitment to advancing recombinant-based technology as a component of pandemic preparedness. The contract can be extended for an additional 24-month option period at BARDA's option, with $82M in additional funding to build on the work Novavax accomplishes during the base period and to support manufacturing scale-up and licensure by the U.S. Food & Drug Administration.
News For NVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2015
09:13 EDTNVAXOn The Fly: Pre-market Movers
HIGHER: Mediwound (MDWD), up 25.5% after being awarded a BARDA contract valued up to $112M... Novavax (NVAX), up 8.4% after RSV F vaccine meets safety endpoints in its Phase 1 clinical trial... Western Digital (WDC), up 11.7% after receiving a $3.78B equity investment by Unisplendour Corporation... Esperion Therapeutics (ESPR), up 9.9% after being upgraded to Neutral from Sell at Chardan and after JPMorgan said they still see longer-term upside in the shares... Pericom Semiconductor (PSEM), up 6.5% after Montage Technology proposes to acquire the company for $18.50 per share... Fiat Chrysler (FCAU), up 5.2% after CNBC reported that the company could launch Ferrari's IPO as soon as Friday. NOTABLE: Ralph Lauren (RL), up 6.4% after appointing Gap's (GPS) global president of Old Navy, Stefan Larsson as CEO... Gap is down 7.4%. DOWN AFTER EARNINGS: Barracuda Networks (CUDA), down 28.5%... Costco (COST), down a half a percent.
September 29, 2015
16:06 EDTNVAXNovavax's RSV F vaccine meets safety endpoints in Phase 1 clinical trial
Subscribe for More Information
14:39 EDTNVAXNovavax weakness a buying opportunity, says FBR Capital
FBR Capital would be buyers of Novavax on the pullback today on confusion over the level of protection infants gained from maternal immunization with the company's RSV F protein vaccine. The firm believes investor perceptions are misplaced and recommend buying the stock as a core holding in an emerging small- cap portfolio.
11:04 EDTNVAXNovavax price target lowered to $15 after maternal RSV data at Piper Jaffray
After Novavax released top-line Phase II RSV-F vaccine data, Piper Jaffray analyst Edward Tenthoff said he is not sure that this vaccine will have dramatic uptake in pregnant women. He lowered his price target on Novavax to $15 from $17 to account for a reduced RSV maternal immunization forecast, but maintains on Overweight rating on the stock, citing the "blockbuster potential" of the company's RSV vaccine in the elderly.
08:49 EDTNVAXNovavax vaccine data results fell short, says Piper Jaffray
Subscribe for More Information
07:00 EDTNVAXNovavax reports women vaccinated with RSV F-protein had a rise in anti-F IgG
Subscribe for More Information
06:49 EDTNVAXNovavax awarded $89M grant for RSV F Vaccine Phase 3 clinical trial
Subscribe for More Information
September 23, 2015
12:11 EDTNVAXNovavax to host analyst and investor day
Analyst and Investor day to be held in New York on September 29 at 9 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use